FOLH1 and prostate cancer: Although PSMA is over-expressed in all prostate cancer cases, the intensity of over-expression varies, and around 50% of tumours show relatively low degrees of PSMA over-expression and correspondingly lower SUVs on PSMA-PET/CT, irrespective of PSA levels [25–27].